CYR61 Is Overexpressed in Human Melanoma Tissue Ex Vivo and Promotes Melanoma Cell Survival and Proliferation Through Its Binding Ligand Integrin β3 In Vitro Authors: Yoon Jin Lee, Ki Dam Kim, Sukh Que Park, Dong Sung Kim, Yu Sung Choi, Hae Seon Nam, Sang Han Lee, Moon Kyun Cho Published: 2024 Dear Editor: Melanoma is a highly metastatic skin cancer that spreads by invading blood vessels and lymphatics, which is associated with cell adhesion molecules1. Integrins are among the most important cell surface receptors that mainly bind extracellular matrix proteins and play a major role in cell adhesion and migration. Notably, in melanoma, integrin has been shown to regulate tumor growth and metastasis1. A wide variety of integrin ligands as well as different mechanisms that regulate integrin receptor functions within the cell have been detected2. Cysteine-rich protein 61 (Cyr61), an extracellular matrix-associated signaling protein of the Cyr61, CTGF, and NOV (CCN) family, has been responsible for increased tumorigenicity, angiogenesis, and metastasis in various cancers3. It is achieved by Cyr61 binding to and activating integrins3. It is well known that integrin β3 is critical for Cyr61-mediated intracellular signaling4. A high expression of Cyr61 has been reported in various human cancers5. This suggests that the overexpression of Cyr61 may play a critical role in the development and progression of these cancers. However, research studies on the involvement of Cyr61 in the progression and metastasis of human melanoma have yielded inconsistent findings6. Moreover, the expression profiles of Cyr61 in human melanoma tissue have not been extensively investigated. So, we aim to identify the expression and functions of Cyr61 in malignant melanoma, which could help to elucidate the potential of Cyr61 as a therapeutic target for melanoma. Furthermore, the effect of integrin β3, a downstream effector of Cyr61 protein, on melanoma survival is also investigated. In this study, we compared the expression levels of Cyr61 and integrin β3 in the human melanoma skin tissues and in normal skin tissue ex vivo. Details about the materials and methods are provided in the Supplementary Data 1. Six normal skin tissues and six malignant melanoma (MM) tissues were obtained from patients who had undergone surgery between December 2015 and December 2018 in the Departments of Plastic and Reconstructive Surgery at the Soonchunhyang University Bucheon Hospital in Korea. The Institutional Review Board of the Seoul Soonchunhyang University Hospital reviewed and approved this research protocol, which involved the use of tissue samples (IRB file No. 2019-04-024). To determine the expression levels of CYR61 and integrin β3 proteins in melanoma tissues (n=6) and normal skin tissues (n=6), western blot analysis was performed. Cyr61 and integrin β3 were overexpressed in all MM compared with normal skin tissues (Fig. 1A). The relative protein expressions were statistically significant (p<0.05). The average score for Cyr61 in MM versus normal skin was 1.796 vs. 0.144, and for integrin β3 was 1.443 vs. 0.524. Moreover, western blot analysis demonstrated that expressions of both Cyr61 and integrin β3 were significantly higher in SK-MEL-2 melanoma cells than in human melanocyte cells (Fig. 1B). The score for Cyr61 was 2.007 vs. 0.027, and integrin β3 1.778 vs 0.249. Cyr61 and integrin β3 were upregulated in melanoma cell lines and tissues, and Cyr61 promotes melanoma cell survival and proliferation through integrin β3. (A) The expression of Cyr61 and integrin β3 proteins in human normal skin and malignant melanoma tissues and relative protein expression in western blot. (B) The expression of Cyr61 and integrin β3 proteins in normal human melanocytes (HEMn-MP) and malignant melanoma cell lines (SK-MEL-2) and relative protein expression in western blot analysis. (C) The cell viability assessment by MTT assay of Cyr61-siRNA and control-siRNA. (D) Inhibitory effects of Cyr61-siRNA and integrin β3-siRNA on anchorage-dependent growth and ability of colony formation in SK-MEL-2 cells. (E) The percentage of apoptotic cells after Annexin V-PE binding assay using a Muse Cell Analyzer. (F) Cell distribution in G0/G1, S, and G2/M phases analyzed by flow cytometry. The quantitative data were presented as mean ± standard deviation. Cyr61: cysteine-rich protein 61, MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, siRNA: small interfering RNA. *p<0.05 compared to untreated controls. Overexpression of Cyr61 in melanoma tissue suggests that it has a role in melanoma progression. Therefore, we investigated the role of Cyr61 and its binding receptor, integrin subunit β3, in cell viability, colony formation, apoptosis, and cell cycle of SK-MEL-2 melanoma cells. Cyr61 and integrin β3 expression were reduced using siRNA in SK-MEL-2, to determine the functional role of Cyr61 and integrin β3 in the development and progression of melanoma. Three-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that the cell viability of both the Cyr61-SiRNA and integrin β3-siRNA treated group was significantly decreased compared to the cells with the control siRNA group (Fig. 1C). The percent of colony formation was decreased in Cyr61-siRNA and integrin β3-siRNA groups compared to that of the untreated control group but the difference was not statistically significant. In both Cyr61-siRNA and integrin β3-siRNA groups, the percent of colony formation was significantly decreased compared to that of the untreated control group (Fig. 1D). The proportion of cells showing early and late phases of apoptosis increased after treatment with either Cyr61-siRNA or integrin β3-siRNA and further increased when treated with both Cyr61-siRNA and integrin β3-siRNA simultaneously (Fig. 1E). Compared to untreated control, there was a decrease in G1 and S levels in the cell cycle in Cyr61-siRNA treated cells and integrin β3-siRNA treated cells. These changes were more exaggerated when treated with both Cyr61-siRNA and integrin β3-siRNA (Fig. 1F). These findings indicated that Cyr61 and integrin β3 promote colony formation, cell survival, and growth in SK-MEL-2 cells and the effect was synergistic. Many studies reported overexpression of Cyr61 in numerous cancers whereas it has been shown that Cyr61 inhibits tumor growth in several malignancies5,7. These paradoxical profiles of Cyr61 in various malignancies suggest that the roles of Cyr61 are complex and may have multiple downstream signaling pathways. An important finding of this study is the characterization of Cyr61 as a tumorigenic enhancer of melanoma by binding with integrin β3. In this study, we found an increase of Cyr61 in human melanoma tissue compared to that in normal human skin ex vivo. The expression of Cyr61 was associated with an aggressive phenotype and increased invasion of melanoma cells8, which is consistent with our findings that Cyr61 promotes cell survival, proliferation, and cancer development in melanoma. In addition, we observed that integrin subunits β3 were overexpressed in human melanoma tissue compared to normal skin. In previous studies, forced overexpression of Cyr61 led to upregulation of its integrin receptor in glioma and breast cancer cells5. In melanoma, overexpression of integrin β3 was reported in melanoma tissue sections, which is consistent with our findings9. Integrin β3 was upregulated in the tumorigenic or vertical growth phase of many primary as well as metastatic melanoma9,10. Hsu et al.10 found that overexpression of integrin β3 resulted in a functional complex with endogenous αv that potentiates the malignant phenotype reminiscent of the progression from the radial to vertical growth phase. In summary, these results indicated that overexpression of Cyr61 may be involved in melanoma development and metastasis by binding integrin β3. Our elucidation of functional effects of Cyr61 in melanoma progression and migration highlights its role in melanoma metastasis through a mechanism involving modulation of tumor cell adhesion. Footnotes FUNDING SOURCE: This work was supported by the Soonchunhyang University Research Fund. CONFLICTS OF INTEREST: The authors have nothing to disclose. DATA SHARING STATEMENT: The data that support the findings of this study are available from the corresponding author upon reasonable request. SUPPLEMENTARY MATERIAL Supplementary Data 1 Study methods References Associated Data Supplementary Materials Supplementary Data 1 Study methods